MiMedx Group Inc. (NASDAQ:MDXG) was down 2.1% during mid-day trading on Monday . The stock traded as low as $7.78 and last traded at $7.82, with a volume of 576,581 shares traded. The stock had previously closed at $7.99.

A number of equities research analysts have recently weighed in on the company. TheStreet raised MiMedx Group from a “hold” rating to a “buy” rating in a research note on Monday, March 21st. First Analysis cut MiMedx Group from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $14.00 to $9.00 in a research note on Wednesday, April 27th. Zacks Investment Research cut MiMedx Group from a “hold” rating to a “sell” rating in a research note on Wednesday, May 18th. Lake Street Capital dropped their price objective on MiMedx Group from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Tuesday, April 19th. Finally, Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $12.00 price objective (down from $13.00) on shares of MiMedx Group in a research note on Thursday, April 7th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. MiMedx Group has a consensus rating of “Buy” and a consensus target price of $10.89.

The stock’s 50-day moving average price is $7.90 and its 200-day moving average price is $8.04. The company has a market capitalization of $853.38 million and a PE ratio of 33.72.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Tuesday, April 26th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by $0.01. The company earned $53.40 million during the quarter, compared to analysts’ expectations of $54.05 million. Equities research analysts anticipate that MiMedx Group Inc. will post $0.31 EPS for the current year.

In other MiMedx Group news, CEO Parker H. Petit purchased 40,000 shares of MiMedx Group stock in a transaction on Friday, May 13th. The shares were bought at an average price of $6.75 per share, with a total value of $270,000.00. Following the purchase, the chief executive officer now directly owns 4,959,121 shares in the company, valued at approximately $33,474,066.75. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Parker H. Petit purchased 50,000 shares of MiMedx Group stock in a transaction on Thursday, May 12th. The shares were acquired at an average cost of $6.74 per share, for a total transaction of $337,000.00. Following the purchase, the chief executive officer now owns 4,919,121 shares in the company, valued at $33,154,875.54. The disclosure for this purchase can be found here.

Other hedge funds and institutional investors have modified their holdings of the company. Parsons Capital Management Inc. RI raised its position in shares of MiMedx Group by 1.5% in the fourth quarter. Parsons Capital Management Inc. RI now owns 718,700 shares of the company’s stock worth $6,734,000 after buying an additional 10,650 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of MiMedx Group by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 672,248 shares of the company’s stock worth $6,299,000 after buying an additional 29,523 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of MiMedx Group by 19.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,041,546 shares of the company’s stock worth $9,759,000 after buying an additional 169,102 shares in the last quarter. Rhumbline Advisers raised its position in shares of MiMedx Group by 13.1% in the fourth quarter. Rhumbline Advisers now owns 129,375 shares of the company’s stock worth $1,212,000 after buying an additional 15,005 shares in the last quarter. Finally, First Trust Advisors LP raised its position in shares of MiMedx Group by 573.5% in the fourth quarter. First Trust Advisors LP now owns 140,573 shares of the company’s stock worth $1,317,000 after buying an additional 119,701 shares in the last quarter.

MiMedx Group, Inc (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.